The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Systemic Vasculitis

Systemic Vasculitis

March 1, 2008 • By Virginia Hughes

  • Tweet
  • Email
Print-Friendly Version / Save PDF

BOSTON—The latest research on the pathophysiology and treatment of small- and large-vessel vasculitides was presented by three international experts at a clinical symposium called “Therapeutic Decisions in Systemic Vasculitis” at the ACR/ARHP Annual Scientific Meeting in Boston last November. Alexandra Villa-Forte, MD, of the rheumatic and immunologic disease department at the Cleveland Clinic, and Carol Langford, MD, MHS, director of the Center for Vasculitis Care and Research at the Cleveland Clinic, discussed treatment options for small-vessel vasculitides. Paul Bacon, MD, professor of rheumatology at the University of Birmingham (U.K.), discussed large-vessel vasculitis.

You Might Also Like
  • Research Offers Insight into Diagnosis, Treatment of Small-Vessel Vasculitis
  • Infliximab, Tocilizumab Can Help in Large Vessel Vasculitis
  • Treatment Challenges, Uncertainty Abound with IgA Vasculitis
Explore This Issue
March 2008
Also By This Author
  • Th17 Cells Explained

For Treatment, Severity is Key

“The most important message,” for practitioners, said Dr. Villa-Forte, is that the treatment approach should be “decided according to the severity of clinical manifestations” and the rate of change of disease progression.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Vasculitides are a diverse group of diseases the result from inflammation of the arteries, veins, capillaries, or other blood vessels. Depending on the extent and duration of vessel involvement, vasculitis can be very serious because it ultimately impedes blood flow to vital organ systems. It affects patients of all ages, can be chronic or acute, and often flares up after long periods of remission.

Each year, only about 500 Americans are diagnosed with Wegener’s granulomatosis—a type of small-vessel vasculitis that eventually causes damage to the lungs and kidneys. The same low incidence is true for large-vessel vasculitis, like Takayasu’s arteritis. Not surprisingly, practicing rheumatologists may not have extensive experience with the management of this family of diseases, and treatment options have been limited.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Vasculitic disease can be difficult to diagnose because they share symptoms—like fatigue, abdominal pain, hypertension, renal insufficiency, and neurologic dysfunction—with many other diseases. A firm diagnosis usually requires a tissue biopsy of one of the organs that has been affected.

Arteriogram showing arteritis in the lower limbs.
Arteriogram showing arteritis in the lower limbs.

Small- and Medium-Vessel Vasculitides

Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitides are among the most common forms of vasculitis. Until recently, the standard treatment of ANCA-associated systemic vasculitis was cyclophosphamide (CYC) and prednisolone. However, both of these drugs can have series side effects.

“The initial protocols for CYC came with high rates of infection, bone marrow suppression and other prolonged types of toxicity,” said Dr. Villa-Forte. Since then, combination therapy of CYC, prednisolone, and methotrexate (MTX) “has made a marked impact on the treatment of the disease. Otherwise it would be mostly fatal.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The first study to directly compare CYC and MTX was conducted by nephrologist Kirsten de Groot and colleagues at the Hannover Medical School in Germany in 2005 (Arthritis Rheum. 2005;52(8):2237-2242). The 100-patient study found that, at six months, the remission rate in patients treated with MTX was 89.8%, just slightly less than the 93.5% remission rate of patients treated with CYC. At the same time, 34% of patients treated with MTX experienced adverse events, while 74% of CYC patients experienced adverse events.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Vasculitis Tagged With: ACR/ARHP Annual Scientific Meeting, arteritis, Clinical research, Diagnostic Criteria, VasculitisIssue: March 2008

You Might Also Like:
  • Research Offers Insight into Diagnosis, Treatment of Small-Vessel Vasculitis
  • Infliximab, Tocilizumab Can Help in Large Vessel Vasculitis
  • Treatment Challenges, Uncertainty Abound with IgA Vasculitis
  • Research Into Causes of Systemic Vasculitis May Lead to Targeted Treatments Say Rheumatologists at the 2013 ACR/ARHP Annual Meeting

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)